Surgery for Drug-Resistant Epilepsy
This observational study is looking at surgery as a treatment for epilepsy that doesn't respond to medication (drug-resistant epilepsy). Researchers want to understand how well surgery works for children and adults with this condition, or for those with epilepsy caused by a tumor. The study will collect information from people who receive standard epilepsy surgery care. Success will be measured by observing the outcomes of surgery over one year. This study is open to people aged 8 to 99 years old who have drug-resistant epilepsy or tumor-related epilepsy. The study status is currently unclear, and it aims to include about 300 participants.
- Study design
- This is an observational study, meaning researchers will collect data from people receiving standard epilepsy care. It aims to include about 300 participants.
- What's involved
- You would undergo standard diagnostic and surgical procedures for epilepsy, which may include invasive monitoring with electrodes.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Surgery as a Treatment for Medically Intractable Epilepsy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Kareem A Zaghloul, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Neurological Disorders and Stroke (NINDS)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Descriptive and/or correlational studies1 year
By providing standard care treatment for patients with drug resistant epilepsy, this protocol allows for descriptive and/or correlational studies based on the data collected through clinical care of these patients including neurophysiological correlates of cognitive function and studies of tissue sample acquired during surgery. Outcomes for patients with tumor related epilepsy will be assessed under a separate protocol, 16-N-0041, Tumor Related Epilepsy.